New Obesity and Diabetes Study Results from Mayo Clinic Described (Weight Loss Outcomes With Semaglutide Based On Diabetes Severity Using the Individualized Metabolic Surgery Score).

A recent study conducted at the Mayo Clinic in Rochester, Minnesota examined the weight loss outcomes of the drug semaglutide in patients with obesity and type 2 diabetes (T2D). The study found that patients with lower scores on the individualized metabolic surgery (IMS) scale, which predicts T2D remission after bariatric surgery, achieved greater weight loss outcomes. However, there was no significant difference in glycemic improvement based on IMS severity. The researchers concluded that further studies are needed to better understand the relationship between T2D severity and semaglutide outcomes. [Extracted from the article]